Flexible Sigmoidoscopy Cuts CRC Incidence, Mortality in Men
MONDAY, April 23, 2018 -- Flexible sigmoidoscopy screening is associated with reduced colorectal cancer (CRC) incidence and mortality in men, but not women, according to a study published online April 24 in the Annals of Internal Medicine.
Øyvind Holme, M.D., Ph.D., from Sørlandet Hospital Kristiansand in Norway, and colleagues conducted a randomized controlled trial involving adults aged 50 to 64 years at baseline without prior CRC. Participants underwent flexible sigmoidoscopy screening between 1999 and 2001 with and without additional fecal blood testing (20,552 patients) versus no screening (78,126 patients).
The adherence rates were 64.7 and 61.4 percent in women and men, respectively. Participants were followed for a median of 14.8 years. The researchers found that the absolute risks for CRC were 1.86 and 2.05 percent in the screening and control groups, respectively, among women (hazard ratio, 0.92; 95 percent confidence interval, 0.79 to 1.07). The corresponding risks were 1.72 and 2.50 percent in men (hazard ratio, 0.66; 95 percent confidence interval, 0.57 to 0.78). In women, the absolute risks for death from CRC were 0.60 and 0.59 percent in the screening and control groups, respectively (hazard ratio, 1.01; 95 percent confidence interval, 0.77 to 1.33). For men, the corresponding risks were 0.49 and 0.81 percent (hazard ratio, 0.63; 95 percent confidence interval, 0.47 to 0.83).
"Offering sigmoidoscopy screening in Norway reduced CRC incidence and mortality in men but had little or no effect in women," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: April 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.